CN114176219A - Hypoallergenic milk protein partial hydrolysis formula food and preparation method thereof - Google Patents
Hypoallergenic milk protein partial hydrolysis formula food and preparation method thereof Download PDFInfo
- Publication number
- CN114176219A CN114176219A CN202111567090.9A CN202111567090A CN114176219A CN 114176219 A CN114176219 A CN 114176219A CN 202111567090 A CN202111567090 A CN 202111567090A CN 114176219 A CN114176219 A CN 114176219A
- Authority
- CN
- China
- Prior art keywords
- compound
- raw materials
- prepared
- following raw
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 43
- 102000014171 Milk Proteins Human genes 0.000 title claims abstract description 35
- 108010011756 Milk Proteins Proteins 0.000 title claims abstract description 35
- 235000021239 milk protein Nutrition 0.000 title claims abstract description 23
- 230000007062 hydrolysis Effects 0.000 title claims abstract description 10
- 238000006460 hydrolysis reaction Methods 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000000774 hypoallergenic effect Effects 0.000 title description 6
- 235000013350 formula milk Nutrition 0.000 claims abstract description 40
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 25
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 25
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 25
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 17
- 235000021119 whey protein Nutrition 0.000 claims abstract description 17
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 16
- 206010016946 Food allergy Diseases 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 10
- 239000008101 lactose Substances 0.000 claims abstract description 10
- 229920002472 Starch Polymers 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000008107 starch Substances 0.000 claims abstract description 5
- 235000019698 starch Nutrition 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 45
- 239000002994 raw material Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 30
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 22
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 22
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 22
- -1 compound choline chloride Chemical class 0.000 claims description 22
- 235000019871 vegetable fat Nutrition 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 16
- 235000015097 nutrients Nutrition 0.000 claims description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 13
- 239000011575 calcium Substances 0.000 claims description 13
- 229910052791 calcium Inorganic materials 0.000 claims description 13
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 13
- 239000008158 vegetable oil Substances 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 229960001295 tocopherol Drugs 0.000 claims description 10
- 229930003799 tocopherol Natural products 0.000 claims description 10
- 235000010384 tocopherol Nutrition 0.000 claims description 10
- 239000011732 tocopherol Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 10
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 108091005658 Basic proteases Proteins 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 235000019743 Choline chloride Nutrition 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 8
- 229960003178 choline chloride Drugs 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 229960000367 inositol Drugs 0.000 claims description 8
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 8
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 7
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 7
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 7
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 7
- 235000019864 coconut oil Nutrition 0.000 claims description 7
- 239000003240 coconut oil Substances 0.000 claims description 7
- 238000007580 dry-mixing Methods 0.000 claims description 7
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 239000003549 soybean oil Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 235000020238 sunflower seed Nutrition 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 229960004203 carnitine Drugs 0.000 claims description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 6
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 6
- 229960005055 sodium ascorbate Drugs 0.000 claims description 6
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 239000002285 corn oil Substances 0.000 claims description 5
- 235000005687 corn oil Nutrition 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 206010070834 Sensitisation Diseases 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 229960000342 retinol acetate Drugs 0.000 claims description 4
- 235000019173 retinyl acetate Nutrition 0.000 claims description 4
- 239000011770 retinyl acetate Substances 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 4
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000008313 sensitization Effects 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- 239000011665 D-biotin Substances 0.000 claims description 2
- 235000000638 D-biotin Nutrition 0.000 claims description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 2
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- 229950006790 adenosine phosphate Drugs 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 108010083498 alkaline elastase Proteins 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 238000009924 canning Methods 0.000 claims description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 2
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 2
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 2
- 239000011666 cyanocobalamin Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 claims description 2
- 239000004193 disodium 5'-ribonucleotide Substances 0.000 claims description 2
- INTPYBRGLGSMRA-WFIJOQBCSA-L disodium cytidine 5'-monophosphate Chemical compound [Na+].[Na+].O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])([O-])=O)O1 INTPYBRGLGSMRA-WFIJOQBCSA-L 0.000 claims description 2
- 235000013896 disodium guanylate Nutrition 0.000 claims description 2
- 235000013890 disodium inosinate Nutrition 0.000 claims description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 2
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 239000011790 ferrous sulphate Substances 0.000 claims description 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 229940099596 manganese sulfate Drugs 0.000 claims description 2
- 239000011702 manganese sulphate Substances 0.000 claims description 2
- 235000007079 manganese sulphate Nutrition 0.000 claims description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 2
- 239000001230 potassium iodate Substances 0.000 claims description 2
- 235000006666 potassium iodate Nutrition 0.000 claims description 2
- 229940093930 potassium iodate Drugs 0.000 claims description 2
- 238000007639 printing Methods 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 239000011781 sodium selenite Substances 0.000 claims description 2
- 235000015921 sodium selenite Nutrition 0.000 claims description 2
- 229960001471 sodium selenite Drugs 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 2
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000012711 vitamin K3 Nutrition 0.000 claims description 2
- 239000011652 vitamin K3 Substances 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 229940041603 vitamin k 3 Drugs 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- 229960001763 zinc sulfate Drugs 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 15
- 235000020256 human milk Nutrition 0.000 abstract description 14
- 210000004251 human milk Anatomy 0.000 abstract description 14
- 208000026935 allergic disease Diseases 0.000 abstract description 13
- 230000007815 allergy Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 5
- 230000003204 osmotic effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 235000021196 dietary intervention Nutrition 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 17
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 239000000413 hydrolysate Substances 0.000 description 11
- 235000016709 nutrition Nutrition 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000020247 cow milk Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000008192 Lactoglobulins Human genes 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000020251 goat milk Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000020215 hypoallergenic milk formula Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960003284 iron Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 108010007119 flavourzyme Proteins 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The application provides a baby milk protein partial hydrolysis formula food with low allergenicity and special medical application suitable for high-risk babies with milk protein allergy and a preparation method thereof; the main protein source of the food is partially hydrolyzed whey protein, wherein the small molecular milk protein, the peptide segment and the amino acid reduce the allergenicity of the large molecular milk protein, and the food has an allergy prevention effect; meanwhile, the maltodextrin and the solid starch sugar partially replace lactose, and the osmotic pressure of the product is adjusted to be close to breast milk. The food product of the present application is an ideal means for early dietary intervention for infant milk protein allergy prevention.
Description
The invention belongs to the field of the following:
the application belongs to the field of foods, particularly the field of infant foods, and particularly provides a low-sensitization infant milk protein partial hydrolysis formula suitable for milk protein-allergic high-risk infants, and a preparation method thereof.
Background art:
allergy, also known medically as allergy, is used to describe a very strong immune response to substances in the environment. Cow's Milk Protein Allergy (CMPA) refers to the immunological reaction (mostly adverse) of a human body to one or several Cow's Milk Proteins (CMP). CMP is often preferred to allergens such as peanuts and eggs, and is the first food allergen that infants come into contact with after birth. Milk protein allergy, difficulty in digestion and absorption of protein due to protease deficiency seriously affects the normal growth and development of infants and young children. According to statistics, the incidence rate of cow milk protein allergy in infants is up to 2% -6%, cow milk protein can cause infantile diarrhea, rash, iron deficiency anemia and dysplasia, and the growth and development of infants are seriously affected. In the event of a severe allergic reaction, laryngeal edema and anaphylactic shock may even be caused, leading to death.
The breast milk is 'gold' ration for the newborn, provides ideal nutrient components for the newborn, endows the newborn with certain immunity, can help the newborn to construct intestinal probiotic groups, and plays an important role in the growth and development of the newborn and the prevention of external bacteria and virus invasion. The World Health Organization (WHO) recommends that pure breast milk be fed for 2 years or more in the first 6 months after birth of infants, however, insufficient or no breast milk is an objective fact, and therefore, for the healthy growth of these infants, infant formulas with cow milk as the main raw material simulating the breast milk component should be born(1). Due to insufficient intestinal development or insufficient immune system development of some infants after birth, the digestive absorption of milk protein has problems, so that food protein allergy is caused, and allergic reactions such as infant vomiting, diarrhea, eczema and the like are easily caused. Infants with a history of lactoprotein allergy and infants with a family genetic disease history belong to the group of high risk lactoprotein allergy. In order to prevent the above-mentioned infants from developing milk protein allergy symptoms, dietary intervention in infancy is an important way to prevent allergy symptoms. The european association of pediatric allergy and clinical immunology (ESPACI) and the european association of pediatric gastroenterology, hepatology and nutrition (ESPGHAN) for high-risk infants: infants are encouraged to breastfeed at least 4 months after birth. If the breast feeding is not pure, hypoallergenic formula milk powder is recommended. American Association of Pediatrics (AAP) recommendations: infants with high risk of allergy due to a significant family allergy history may benefit from a pure breast-feeding, hypoallergenic formula or partially hydrolyzed formula milk powder(2)。
Infant formula for special medical use refers to a powdered or liquid formula designed to meet the nutritional needs of infants suffering from special medical conditions such as special disorders, diseases, or medical conditions. Under the guidance of doctors or clinical dieticians, when the infant formula feed is eaten alone or in combination with other foods, the energy and the nutrient contents of the infant formula feed can meet the growth and development requirements of infants with the special condition of 0-6 months of age.
The main drawbacks of such products of the prior art are: active substances are added, which does not conform to GB 25596 and a registration management method; in the wet process production, the whole process flow involves more equipment, the cost is higher, the process is relatively complex, and heat-sensitive and photosensitive nutrients are easy to lose; the vegetable oil is not subjected to microcapsule embedding, and the grease is easy to oxidize and deteriorate in shelf life and has poor stability; the product has small granularity, lumps and poor reconstitution property; the product formula design does not conform to GB 25596, and does not combine dietary nutrient reference intake (2013) of Chinese residents and breast milk data. For example: CN112167360A hypoallergenic infant formula goat milk powder is added with complete protein, and simultaneously added with functional raw materials of osteopontin and ganglioside which do not meet the GB 25596 regulation and the product registration requirements; CN111972496A A milk powder suitable for milk protein allergy high risk infants uses maltodextrin to completely replace lactose, the invention reserves partial lactose, is beneficial to digestion and absorption and is beneficial to mineral absorption; CN104814146A infant formula milk powder compounded by cow and goat milk and a preparation method thereof are added with complete goat milk protein, so that cow milk protein allergy is effectively relieved; CN104719610A A hypoallergenic milk protein powder and its preparation method do not meet the requirements of GB 25596 regulations and can not meet the nutritional requirements of infants of 0-6 months old; CN101836676A soymilk powder and a preparation method thereof are infant formula milk powder without adding lactose and milk protein. The technical scheme is suitable for milk protein allergic people, but does not meet the GB 25596 regulation requirements and the requirements related to the registration management method of the formula food with special medical application.
Disclosure of Invention
Under the circumstances, the technical problem to be solved by the invention is to provide a low-allergenicity infant milk protein partial hydrolysis formula food with special medical application for infants with high risk of milk protein allergy and a preparation method thereof, so as to ensure nutrition required by the growth and development of infants and avoid the milk protein allergy of newbornGrow and enhance the immunity of the newborn. The use of partially hydrolyzed milk protein formula can reduce the risk of the infant ingesting the allergen, milk protein, thereby reducing the risk of the infant being allergic to milk protein molecules(3)(ii) a The main protein source of the invention is partially hydrolyzed whey protein, micromolecule milk protein, peptide segment and amino acid reduce the sensitization of macromolecule milk protein, and the invention has the allergy prevention effect, simultaneously, maltodextrin and solid starch sugar partially replace lactose, and the osmotic pressure of the product is adjusted to be close to breast milk. The invention is an ideal means for early dietary intervention of infant milk protein allergy prevention.
In one aspect, the present application provides a hypoallergenic infant milk protein partial hydrolysis formula for use in infants at high risk of milk protein allergy for special medical use, said formula consisting essentially of, in parts by weight:
1627-770 parts of vegetable fat powder, 2216-251 parts of vegetable fat powder, 18-22 parts of fructo-oligosaccharide, 8.8-13.2 parts of compound choline chloride, 5.6-8.4 parts of compound potassium chloride, 4-6 parts of compound calcium hydrophosphate, 4-6 parts of compound mineral substance, 2.8-4.2 parts of compound inositol, 2.4-4.6 parts of tricalcium phosphate, 2.7-4.1 parts of compound vitamin, 1.6-2.4 parts of compound sodium chloride, 0.8-1.2 parts of calcium carbonate, 0.4-0.6 part of compound carnitine and 0.4-0.6 part of compound nucleotide.
Furthermore, the indexes of the vegetable fat powder 1 and the vegetable fat powder 2 such as molecular weight distribution are as follows: the mass percentage of the peptide segment to the fragment with the molecular mass more than 10000Da is 0-20%, the mass percentage of the peptide segment to the fragment with the molecular mass of 5000-10000 Da is 0-10%, the mass percentage of the peptide segment to the fragment with the molecular mass of 500-5000 Da is 40-70%, and the mass percentage of the peptide segment to the fragment with the molecular mass less than 500Da is 20-50%.
Further, per 1kg of the food product produced, the vegetable fat powder 1 is prepared from the following raw materials: 283-346 g of lactose, 164-200 g of partially hydrolyzed whey protein powder, 7-143 g of vegetable oil 111, 250.3-61.5 g of vegetable oil, 7.832-11.748 g of compound calcium hydrophosphate, 3.91-5.87 g of mono-diglycerol fatty acid ester, 1.12-1.68 g of L-sodium ascorbate, 0.185-0.277 g of ascorbyl palmitate, 0.185-0.277 g of phospholipid, and 0.146-0.218 g of mixed tocopherol concentrate.
For every 1kg of the food, the vegetable oil 1 is prepared from the following raw materials:
54.99-67.21 g of sunflower seed oil, 25.74-31.46 g of low erucic acid rapeseed oil, 24.57-30.03 g of soybean oil, 11.7-14.3 g of coconut oil, 0.0312-0.0468 g of mixed tocopherol concentrate and 0.0208-0.0312 g of ascorbyl palmitate.
For every 1kg of the food, the vegetable oil 2 is prepared from the following raw materials:
12.58-15.38 g of corn oil, 11.57-14.15 g of sunflower seed oil, 11.07-13.53 g of soybean oil, 10.06-12.30 g of low erucic acid rapeseed oil, 5.03-6.15 g of coconut oil, 13.44-20.16 mg of mixed tocopherol concentrate and 8.96-13.44 mg of ascorbyl palmitate.
Every 1kg of the food is produced, the compound calcium hydrophosphate is prepared from the following raw materials:
7.8304-11.7456 g of calcium hydrogen phosphate, 0.784-1.176 mg of maltodextrin and 0.784-1.176 mg of ascorbyl palmitate.
Further, per 1kg of the food product produced, the vegetable fat powder 2 is prepared from the following raw materials: 57.86-70.72 g of solid starch sugar, 54-66 g of anhydrous cream, 49.68-60.72 g of partially hydrolyzed whey protein powder, 41-51 g of maltodextrin, 210.8-13.2 g of vegetable oil, 1.36-2.04 g of mono-diglycerol fatty acid ester, 0.4-0.6 g of L-sodium ascorbate, 0.0616-0.0924 g of phospholipid, 0.0576-0.0864 g of ascorbyl palmitate, and 0.0464-0.0696 g of mixed tocopherol concentrate.
For every 1kg of the food, the vegetable oil 2 is prepared from the following raw materials:
2.7-3.3 g of corn oil, 2.48-3.04 g of sunflower seed oil, 2.38-2.90 g of soybean oil, 2.16-2.64 g of low erucic acid rapeseed oil, 1.08-1.32 g of coconut oil, 2.88-4.32 mg of mixed tocopherol concentrate and 1.92-2.88 mg of ascorbyl palmitate.
Further, each 1kg of said food product produced,
the compound choline chloride is prepared from the following raw materials:
7.74-11.61 g of maltodextrin, 1.056-1.584 g of choline chloride and 0.88-1.32 mg of ascorbyl palmitate;
the compound potassium chloride is prepared from the following raw materials:
4.48-6.72 g of potassium chloride, 1.12-1.68 g of maltodextrin and 0.56-0.84 mg of ascorbyl palmitate;
the compound calcium hydrophosphate is prepared from the following raw materials:
3.9992-5.9988 g of calcium hydrophosphate, 0.4-0.6 mg of maltodextrin and 0.4-0.6 mg of ascorbyl palmitate;
the compound mineral is prepared from the following raw materials:
2.568-3.852 g of magnesium sulfate, 1.173-1.760 g of maltodextrin, 0.142-0.212 g of ferrous sulfate, 0.103-0.155 g of zinc sulfate, 9.36-14.04 mg of copper sulfate, 2.936-4.404 mg of manganese sulfate, 1.336-2.004 mg of potassium iodate and 0.266-0.400 mg of sodium selenite;
the compound inositol is prepared from the following raw materials:
1.68-2.52 g of maltodextrin, 1.12-1.68 g of inositol and 0.28-0.42 mg of ascorbyl palmitate.
The compound vitamin is prepared from the following raw materials:
1.33-1.99 g of maltodextrin, 0.32-0.48 g of taurine, 0.32-0.48 g of L-sodium ascorbate, 0.2384-0.3576 g of 50% of dl-alpha-tocopherol acetate, 0.0488-0.0732 g of 11.5% of retinyl acetate, 0.048-0.072 g of nicotinamide, 0.0448-0.0672 g of D-calcium pantothenate, 0.25% of cholecalciferol 0.0288-0.0432 g, 0.0116-0.0174 g of riboflavin, 5.36-8.04 mg of thiamine hydrochloride, 3.74-5.60 mg of pyridoxine hydrochloride, 0.8-1.2 mg of folic acid, 0.534-0.800 mg of plant menadione, 0.264-0.396 mg of D-biotin and 0.016-0.024 mg of cyanocobalamine;
the compound sodium chloride is prepared from the following raw materials:
1.28 to 1.92g of sodium chloride, 0.32 to 0.48g of maltodextrin and 0.16 to 0.24mg of retinyl acetate.
The compound carnitine is prepared from the following raw materials:
0.22-0.33 g of maltodextrin, 0.18-0.27 g of L-carnitine tartrate and 0.04-0.06 mg of ascorbyl palmitate.
The compound nucleotide is prepared from the following raw materials:
0.1584-0.2376 g of disodium 5' -cytidylate, 0.0888-0.1332 g of disodium 5' -uridylate, 0.076-0.114 g of adenosine 5' -monophosphate, 0.0504-0.0756 g of disodium 5' -inosinate and 0.0264-0.0396 g of disodium 5' -guanylate.
Further, the partially hydrolyzed whey protein powder is prepared by enzymatic hydrolysis of whey protein with alkali protease and elastase.
Further, the partially hydrolyzed whey protein powder is prepared by enzymolysis of whey protein by using 5% and 3% of alkaline protease and elastase in an enzyme/substrate mass ratio; the enzymolysis conditions are pH 8.0, temperature 45 ℃ and time 5 hours.
In another aspect, the present application provides a method for preparing the food product, comprising the steps of:
(1) checking and accepting raw materials and auxiliary materials: executing a checking system of the arrived goods; sampling and inspecting according to related national standards or corresponding enterprise internal control standards;
(2) preparing materials: inspecting qualified materials, and preparing the materials into a feeding room according to a production plan;
(3) removing the outer bag: removing the outer package and wiping the outer surface of the inner package;
(4) feeding: the material adhered with the bar code passes through a tunnel type ultraviolet sterilizer, wherein the number of ultraviolet lamps is not less than 18, the ultraviolet intensity is not less than 70uw/cm2, and the distance between powder bags is not less than 10 cm;
(5) premixing: accurately putting compound sodium chloride, calcium carbonate, compound carnitine and compound nucleotide into a premixer, wherein the mixing amount is not less than 5kg and not more than 7.5kg each time, carrying out physical mixing for 3 minutes, and subpackaging and marking after the mixed nutrient premix packet is qualified through sensory inspection;
(6) weighing: accurately weighing the vegetable fat powder 1 and the vegetable fat powder 2 according to the formula of the product;
(7) feeding: checking the materials and detecting a powder sieve, and respectively feeding vegetable fat powder 1, vegetable fat powder 2, compound choline chloride, compound potassium chloride, compound calcium hydrophosphate, compound mineral substances, compound inositol, compound vitamins, a nutrient premix bag, fructo-oligosaccharide and tricalcium phosphate;
(8) sieving: the number of the vibrating screen meshes is 12 meshes;
(9) powder conveying: conveying the materials into a dry mixer by using clean compressed air at one time under positive pressure;
(10) dry mixing: setting the dry mixing clean compressed air pressure to be 0.4-0.5MPa and the dry mixing time to be 480 s;
(11) and (3) metal detection: the metal detector can detect iron with a thickness of more than or equal to 0.7mm and stainless steel with a thickness of more than or equal to 1.0 mm;
(12) inner packaging, including canning, weighing, encapsulation: packaging in a packaging machine by a metal detector, wherein the packaging machine is automatically filled, metered, filled with nitrogen and sealed; the residual oxygen content in the hearing is less than or equal to 3 percent after nitrogen filling;
(13) sterilizing: sterilizing the empty tin for at least 10s by using a tunnel type ultraviolet sterilizer, and then entering a cleaning operation area; sterilizing the bottom cover by a transfer window type ultraviolet sterilizer for at least 15min, and then entering a cleaning operation area;
(14) and (3) outer packaging: the method comprises date printing, scanning and removing, plastic cover buckling, boxing, box sealing, code spraying and stacking;
(15) finished products are put in storage: and (5) checking, and after the inspection is qualified, distributing and delivering goods.
Has the advantages that:
the fatty acid composition of the product is reasonably adjusted by adding the sunflower seed oil, the soybean oil, the low erucic acid rapeseed oil, the coconut oil, the corn oil and the anhydrous cream, so that the fatty acid composition of the infant milk protein partial hydrolysis formula food with special medical application is closer to the composition of fatty acid in breast milk, the nutrition required by the growth and development of infants is ensured, and the immunity of newborns is enhanced.
The dietary fiber fructo-oligosaccharide is added, so that the proliferation of bifidobacteria in intestinal tracts is promoted, the development and maturity of intestinal tracts of infants are promoted, and the immune function of the infants is enhanced, so that the infants are protected from infection and illness.
Close to the osmotic pressure of breast milk and better tolerance.
The maltodextrin and the solid starch sugar are used for replacing lactose, the maltodextrin is easy to digest and absorb, the burden of the intestinal tract is not increased, and the osmotic pressure can be properly reduced.
The combination of various nutrients (nucleotide, taurine, vitamin A, vitamin D, vitamin E, pantothenic acid and iron) is beneficial to enhancing the immunity of the baby.
Partially hydrolyzed whey protein, lactose (promoting the growth of beneficial bacteria in the intestinal tract and the absorption of calcium and other trace elements), fructo-oligosaccharide and nucleotide combination promote the digestion and absorption of the intestinal tract and maintain the normal function of the intestinal tract.
Lactose, choline, taurine and iodine are beneficial to brain development.
The low-allergenicity infant partial hydrolysis formula food with special medical application is close to breast milk in composition, guarantees nutrition required by infant growth and development, avoids cow milk protein allergy of newborn, and enhances immunity of newborn, so that newborn infection and illness are prevented.
Drawings
FIG. 1 compares the product nutritional data of the present application with the GB 25596 minimum;
FIG. 2 is a comparison of the product nutrient data of the present application with the GB 25596 maximum;
FIG. 3 is a comparison of nutritional data for a product of the present application with breast milk;
Detailed Description
EXAMPLE 1 preparation of the product of the present application
The products of the present application were prepared according to the methods and processes of the summary of the invention section:
the invention relates to a low-allergenicity infant milk protein partial hydrolysis formula food with special medical application, which is suitable for milk protein allergic high-risk infants, wherein 250-295 kJ energy is provided for each 100mL of brewing liquid, the average osmotic pressure is about 280mOsm/kg, and the nutrient indexes all meet the corresponding requirements in GB 25596. The specific nutrient components are shown in table 1:
table 1: the nutritional ingredients are provided per 100kJ of food
The powder partially hydrolyzed formula food for infants with special medical application based on hydrolyzed whey protein, provided by the invention, has the advantages of breast milk imitation design, excellent amino acid mode, reasonable fatty acid proportion, long shelf life and convenience in carrying, and the energy and nutritional ingredients of the partially hydrolyzed formula food can meet the growth and development requirements of infants with special medical conditions of 0-6 months old when the partially hydrolyzed formula food is eaten alone or in combination with other foods.
As can be seen from the figure 1 and figure 2, each nutrient of the product is within the GB 25596 requirement range, and can meet the growth and development requirements of infants with 0-6 months old special medical conditions as a single nutrient source. Figure 3 shows that the product nutrients are similar to breast milk (with a manganese content that is too large, primarily due to the varying content of breast milk).
Example 2 Effect of different enzymatic methods on product sensitization
The enzymolysis conditions are unified to pH 8.0, temperature 45 ℃ and time 5 hours (several proteases can exert higher effect).
Hydrolysate 1: 5% and 3% enzyme/substrate mass ratio of alkaline protease enzyme and elastase;
hydrolysate 2: 4% and 4% enzyme/substrate mass ratio of alkaline protease enzyme and elastase;
hydrolysate 3: 4% and 4% enzyme/substrate mass ratio of alkaline protease enzyme and papain;
hydrolysate 4: 4% and 4% of an alkaline protease enzyme and a complex flavourzyme in an enzyme/substrate mass ratio;
hydrolysate 5: 7% alkaline protease;
(only a portion of the representative formula is shown, and a large number of the verification formulas are not shown due to space)
Molecular weight distribution:
SDS electrophoresis results show that the peptide fragments of the above hydrolysates are distributed similarly, mainly in about 5000. Determination of level of sensitized cells:
serum from patients diagnosed with allergy to bovine milk beta-lactoglobulin (specific IgE >0.8KUA/L) was obtained by a cooperative medical facility and the serum pool used for the test was a mixture of the sera of 17 patients.
Recovering and passaging the purchased cryopreserved KU812 cells; adding 2% cow milk beta-lactoglobulin into the culture medium to confirm serum pool serum (blank group is sterile buffer solution) of an allergic patient, and then incubating for 12 hours to enable cells to be in a sensitized state; adding a sample with the protein concentration of 10mg/mL (a negative control group is sterile buffer solution) with the volume of 1% of the culture medium, and incubating for 6 hours; after Triton X-100 lysis, β -HEX was detected using the above kit and the β -HEX release rate was calculated: β -HEX release (100%) × (sample group OD value-negative group OD value)/(positive group OD value-negative group OD value) × 100%.
The results are shown in table 2 below:
TABLE 2 beta-HEX Release rates for various hydrolyzed whey proteins
| Sample (I) | beta-HEX Release Rate (%) |
| Hydrolysate 1 | 42.73 |
| Hydrolysate 2 | 25.21 |
| Hydrolysate 3 | 29.33 |
| Hydrolysate 4 | 34.98 |
| Hydrolysate 5 | 36.29 |
The results show that the enzymolysis effect of 5 percent and 3 percent of the enzyme/substrate mass ratio of the alkaline protease and the elastase is obviously better than that of other enzymes or ratios, and the allergenicity is effectively reduced. According to the description in reference 4, we further detected the presence of the peptide fragment of the allergy epitope of beta-lactoglobulin, and the peptide fragments 34-40 and 73-82 in the hydrolysate 1 were hardly detected compared with other hydrolysates, which further proved the hypoallergenic effect.
Reference documents:
1. the technology of making incense, Zhanzhiwu, hydrolyzing milk protein and the functional characteristics of its product [ J ] Chinese dairy industry, 2005,174(5):40-45.
2. The development of antiallergic research on hydrolyzed formula milk powder and its market development and application [ J ]. food industry, 2015,36(9): 247-.
3. Han jun hua, a standard implementation guide of a food series for special medical use [ Z ]. first edition, chinese quality inspection press, chinese standards press, 2015.
Fritsche R. et al, IgE-mediated rat cell triggering with typing and synthesizing peptides of bone beta-lactose, Int Arch Allergy Immunol, 2005, Vol.138, No. 4.
Claims (9)
1. A baby milk protein partial hydrolysis formula suitable for low sensitization of milk protein allergy high risk babies, which is characterized in that: the formula food mainly comprises the following components in parts by weight:
1627-770 parts of vegetable fat powder, 2216-251 parts of vegetable fat powder, 18-22 parts of fructo-oligosaccharide, 8.8-13.2 parts of compound choline chloride, 5.6-8.4 parts of compound potassium chloride, 4-6 parts of compound calcium hydrophosphate, 4-6 parts of compound mineral substance, 2.8-4.2 parts of compound inositol, 2.4-4.6 parts of tricalcium phosphate, 2.7-4.1 parts of compound vitamin, 1.6-2.4 parts of compound sodium chloride, 0.8-1.2 parts of calcium carbonate, 0.4-0.6 part of compound carnitine and 0.4-0.6 part of compound nucleotide.
2. The food product of claim 1, wherein the molecular weight distributions of the vegetable fat powder 1 and the vegetable fat powder 2 are as follows: the mass percentage of the peptide segment to the fragment with the molecular mass more than 10000Da is 0-20%, the mass percentage of the peptide segment to the fragment with the molecular mass of 5000-10000 Da is 0-10%, the mass percentage of the peptide segment to the fragment with the molecular mass of 500-5000 Da is 40-70%, and the mass percentage of the peptide segment to the fragment with the molecular mass less than 500Da is 20-50%.
3. The food product according to claim 1 or 2, wherein the vegetable fat powder 1 is prepared from the following raw materials per 1kg of the food product produced:
283-346 g of lactose, 164-200 g of partially hydrolyzed whey protein powder, 1117-143 g of vegetable oil, 250.3-61.5 g of vegetable oil, 7.832-11.748 g of compound calcium hydrophosphate, 3.91-5.87 g of mono-diglycerol fatty acid ester, 1.12-1.68 g of L-sodium ascorbate, 0.185-0.277 g of ascorbyl palmitate, 0.185-0.277 g of phospholipid, and 0.146-0.218 g of mixed tocopherol concentrate;
for every 1kg of the food, the vegetable oil 1 is prepared from the following raw materials:
54.99-67.21 g of sunflower seed oil, 25.74-31.46 g of low erucic acid rapeseed oil, 24.57-30.03 g of soybean oil, 11.7-14.3 g of coconut oil, 0.0312-0.0468 g of mixed tocopherol concentrate and 0.0208-0.0312 g of ascorbyl palmitate;
for every 1kg of the food, the vegetable oil 2 is prepared from the following raw materials:
12.58 to 15.38g of corn oil, 11.57 to 14.15g of sunflower seed oil, 11.07 to 13.53g of soybean oil, 10.06 to 12.30g of low erucic acid rapeseed oil, 5.03 to 6.15g of coconut oil, 13.44 to 20.16mg of mixed tocopherol concentrate, 8.96 to 13.44mg of ascorbyl palmitate,
every 1kg of the food is produced, the compound calcium hydrophosphate is prepared from the following raw materials:
7.8304-11.7456 g of calcium hydrogen phosphate, 0.784-1.176 mg of maltodextrin and 0.784-1.176 mg of ascorbyl palmitate.
4. A food product according to any one of claims 1 to 3, wherein the vegetable fat powder 2 is prepared from the following raw materials per 1kg of the food product produced:
57.86-70.72 g of solid starch sugar, 54-66 g of anhydrous cream, 49.68-60.72 g of partially hydrolyzed whey protein powder, 41-51 g of maltodextrin, 210.8-13.2 g of vegetable oil, 1.36-2.04 g of mono-diglycerol fatty acid ester, 0.4-0.6 g of L-sodium ascorbate, 0.0616-0.0924 g of phospholipid, 0.0576-0.0864 g of ascorbyl palmitate, and 0.0464-0.0696 g of mixed tocopherol concentrate;
for every 1kg of the food, the vegetable oil 2 is prepared from the following raw materials:
2.7-3.3 g of corn oil, 2.48-3.04 g of sunflower seed oil, 2.38-2.90 g of soybean oil, 2.16-2.64 g of low erucic acid rapeseed oil, 1.08-1.32 g of coconut oil, 2.88-4.32 mg of mixed tocopherol concentrate and 1.92-2.88 mg of ascorbyl palmitate.
5. A food product according to any one of claims 1-4, wherein for every 1kg of the food product produced,
the compound choline chloride is prepared from the following raw materials:
7.74-11.61 g of maltodextrin, 1.056-1.584 g of choline chloride and 0.88-1.32 mg of ascorbyl palmitate; the compound potassium chloride is prepared from the following raw materials:
4.48-6.72 g of potassium chloride, 1.12-1.68 g of maltodextrin and 0.56-0.84 mg of ascorbyl palmitate; the compound calcium hydrophosphate is prepared from the following raw materials:
3.9992-5.9988 g of calcium hydrophosphate, 0.4-0.6 mg of maltodextrin and 0.4-0.6 mg of ascorbyl palmitate;
the compound mineral is prepared from the following raw materials:
2.568-3.852 g of magnesium sulfate, 1.173-1.760 g of maltodextrin, 0.142-0.212 g of ferrous sulfate, 0.103-0.155 g of zinc sulfate, 9.36-14.04 mg of copper sulfate, 2.936-4.404 mg of manganese sulfate, 1.336-2.004 mg of potassium iodate and 0.266-0.400 mg of sodium selenite;
the compound inositol is prepared from the following raw materials:
1.68-2.52 g of maltodextrin, 1.12-1.68 g of inositol and 0.28-0.42 mg of ascorbyl palmitate;
the compound vitamin is prepared from the following raw materials:
1.33-1.99 g of maltodextrin, 0.32-0.48 g of taurine, 0.32-0.48 g of L-sodium ascorbate, 0.2384-0.3576 g of 50% of dl-alpha-tocopherol acetate, 0.0488-0.0732 g of 11.5% of retinyl acetate, 0.048-0.072 g of nicotinamide, 0.0448-0.0672 g of D-calcium pantothenate, 0.25% of cholecalciferol 0.0288-0.0432 g, 0.0116-0.0174 g of riboflavin, 5.36-8.04 mg of thiamine hydrochloride, 3.74-5.60 mg of pyridoxine hydrochloride, 0.8-1.2 mg of folic acid, 0.534-0.800 mg of plant menadione, 0.264-0.396 mg of D-biotin and 0.016-0.024 mg of cyanocobalamine;
the compound sodium chloride is prepared from the following raw materials:
1.28 to 1.92g of sodium chloride, 0.32 to 0.48g of maltodextrin and 0.16 to 0.24mg of retinyl acetate;
the compound carnitine is prepared from the following raw materials:
0.22-0.33 g of maltodextrin, 0.18-0.27 g of L-carnitine tartrate and 0.04-0.06 mg of ascorbyl palmitate;
the compound nucleotide is prepared from the following raw materials:
0.1584-0.2376 g of disodium 5' -cytidylate, 0.0888-0.1332 g of disodium 5' -uridylate, 0.076-0.114 g of adenosine 5' -monophosphate, 0.0504-0.0756 g of disodium 5' -inosinate and 0.0264-0.0396 g of disodium 5' -guanylate.
6. A food product as claimed in any one of claims 1 to 5 wherein the partially hydrolysed whey protein powder is produced by enzymatic hydrolysis of whey protein using alkali protease and elastase.
7. The food product of claim 6 wherein the partially hydrolyzed whey protein powder is prepared by enzymatic hydrolysis of whey protein with 5% and 3% alkaline protease and elastase by mass of enzyme/substrate; the enzymolysis conditions are pH 8.0, temperature 45 ℃ and time 5 hours.
8. A method of preparing a food product according to any one of claims 1 to 7, comprising the steps of:
(1) checking and accepting the raw materials and the auxiliary materials; (2) preparing materials; (3) removing the outer bag; (4) feeding; (5) premixing; (6) weighing; (7) feeding; (8) sieving; (9) conveying the powder; (10) dry mixing; (11) detecting metal; (12) packaging in an inner package; (13) sterilizing by hearing; (14) packaging; (15) and (6) warehousing the finished product.
9. The preparation method according to claim 8, wherein the steps are specifically:
(1) checking and accepting raw materials and auxiliary materials: executing a checking system of the arrived goods; sampling and inspecting according to related national standards or corresponding enterprise internal control standards;
(2) preparing materials: inspecting qualified materials, and preparing the materials into a feeding room according to a production plan;
(3) removing the outer bag: removing the outer package and wiping the outer surface of the inner package;
(4) feeding: the material adhered with the bar code passes through a tunnel type ultraviolet sterilizer, wherein the number of ultraviolet lamps is not less than 18, the ultraviolet intensity is not less than 70uw/cm2, and the distance between powder bags is not less than 10 cm;
(5) premixing: accurately putting compound sodium chloride, calcium carbonate, compound carnitine and compound nucleotide into a premixer, wherein the mixing amount is not less than 5kg and not more than 7.5kg each time, carrying out physical mixing for 3 minutes, and subpackaging and marking after the mixed nutrient premix packet is qualified through sensory inspection;
(6) weighing: accurately weighing the vegetable fat powder 1 and the vegetable fat powder 2 according to the formula of the product;
(7) feeding: checking the materials and detecting a powder sieve, and respectively feeding vegetable fat powder 1, vegetable fat powder 2, compound choline chloride, compound potassium chloride, compound calcium hydrophosphate, compound mineral substances, compound inositol, compound vitamins, a nutrient premix bag, fructo-oligosaccharide and tricalcium phosphate;
(8) sieving: the number of the vibrating screen meshes is 12 meshes;
(9) powder conveying: conveying the materials into a dry mixer by using clean compressed air at one time under positive pressure;
(10) dry mixing: setting the dry mixing clean compressed air pressure to be 0.4-0.5MPa and the dry mixing time to be 480 s;
(11) and (3) metal detection: the metal detector can detect iron with a thickness of more than or equal to 0.7mm and stainless steel with a thickness of more than or equal to 1.0 mm;
(12) inner packaging, including canning, weighing, encapsulation: packaging in a packaging machine by a metal detector, wherein the packaging machine is automatically filled, metered, filled with nitrogen and sealed; the residual oxygen content in the hearing is less than or equal to 3 percent after nitrogen filling;
(13) sterilizing: sterilizing the empty tin for at least 10s by using a tunnel type ultraviolet sterilizer, and then entering a cleaning operation area; sterilizing the bottom cover by a transfer window type ultraviolet sterilizer for at least 15min, and then entering a cleaning operation area;
(14) and (3) outer packaging: the method comprises date printing, scanning and removing, plastic cover buckling, boxing, box sealing, code spraying and stacking;
(15) finished products are put in storage: and (5) checking, and after the inspection is qualified, distributing and delivering goods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111567090.9A CN114176219B (en) | 2021-12-20 | 2021-12-20 | Hypoallergenic milk protein partial hydrolysis formula food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111567090.9A CN114176219B (en) | 2021-12-20 | 2021-12-20 | Hypoallergenic milk protein partial hydrolysis formula food and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114176219A true CN114176219A (en) | 2022-03-15 |
| CN114176219B CN114176219B (en) | 2022-10-04 |
Family
ID=80544597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111567090.9A Active CN114176219B (en) | 2021-12-20 | 2021-12-20 | Hypoallergenic milk protein partial hydrolysis formula food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114176219B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106086136A (en) * | 2016-07-01 | 2016-11-09 | 西北民族大学 | A kind of lactoalbumin hydrolysate and its preparation method and application |
| CN109730306A (en) * | 2018-12-29 | 2019-05-10 | 贝因美（杭州）食品研究院有限公司 | A kind of diabetic milk albumen depth hydrolysis' infant formula and preparation method thereof |
| CN110037112A (en) * | 2019-04-11 | 2019-07-23 | 甘肃华羚生物技术研究中心 | A kind of efficiently property digested and assimilated milk power for infant and young children and its production method |
| CN111631261A (en) * | 2020-06-08 | 2020-09-08 | 沈阳农业大学 | Liquid milk preparation method based on reduction of cow milk sensitization |
| CN111972496A (en) * | 2020-08-25 | 2020-11-24 | 广州市美素力营养品有限公司 | Milk powder suitable for milk protein allergic high-risk infants |
| CN113519686A (en) * | 2021-07-22 | 2021-10-22 | 青岛圣桐营养食品有限公司 | Infant milk protein partial hydrolysis formula food and preparation method thereof |
| CN113519687A (en) * | 2021-07-22 | 2021-10-22 | 青岛圣桐营养食品有限公司 | Infant milk protein partial hydrolysis formula food for special medical use |
-
2021
- 2021-12-20 CN CN202111567090.9A patent/CN114176219B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106086136A (en) * | 2016-07-01 | 2016-11-09 | 西北民族大学 | A kind of lactoalbumin hydrolysate and its preparation method and application |
| CN109730306A (en) * | 2018-12-29 | 2019-05-10 | 贝因美（杭州）食品研究院有限公司 | A kind of diabetic milk albumen depth hydrolysis' infant formula and preparation method thereof |
| CN110037112A (en) * | 2019-04-11 | 2019-07-23 | 甘肃华羚生物技术研究中心 | A kind of efficiently property digested and assimilated milk power for infant and young children and its production method |
| CN111631261A (en) * | 2020-06-08 | 2020-09-08 | 沈阳农业大学 | Liquid milk preparation method based on reduction of cow milk sensitization |
| CN111972496A (en) * | 2020-08-25 | 2020-11-24 | 广州市美素力营养品有限公司 | Milk powder suitable for milk protein allergic high-risk infants |
| CN113519686A (en) * | 2021-07-22 | 2021-10-22 | 青岛圣桐营养食品有限公司 | Infant milk protein partial hydrolysis formula food and preparation method thereof |
| CN113519687A (en) * | 2021-07-22 | 2021-10-22 | 青岛圣桐营养食品有限公司 | Infant milk protein partial hydrolysis formula food for special medical use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114176219B (en) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dewey | Reducing stunting by improving maternal, infant and young child nutrition in regions such as South Asia: evidence, challenges and opportunities | |
| Brown et al. | Effect of dietary fiber (soy polysaccharide) on the severity, duration, and nutritional outcome of acute, watery diarrhea in children | |
| Anderson et al. | History and current status of infant formulas | |
| CN101828708B (en) | Heme and polypeptide composition and preparation method thereof | |
| TW415846B (en) | Low buffer nutritional composition | |
| Thakwalakwa et al. | Impact of lipid‐based nutrient supplements and corn–soy blend on energy and nutrient intake among moderately underweight 8–18‐month‐old children participating in a clinical trial | |
| CN111937964A (en) | Formula milk powder for promoting overall development of children and application thereof | |
| US20110110905A1 (en) | Infant Colic Supplement | |
| Keusch et al. | Selective primary health care: strategies for control of disease in the developing world. XXIII. Control of infection to reduce the prevalence of infantile and childhood malnutrition | |
| CN114176219B (en) | Hypoallergenic milk protein partial hydrolysis formula food and preparation method thereof | |
| AU2013250712B2 (en) | Growth enhancement of infants | |
| Kerner Jr | Formula allergy and intolerance | |
| Walker | Allergen absorption in the intestine: implication for food allergy in infants | |
| CN114651967B (en) | Infant nutrition supplement for special medical use and preparation method thereof | |
| O'Connor | Failure to thrive with breast feeding | |
| CN114190543B (en) | Lactose-free formula food for infants with low osmotic pressure and special medical application | |
| Castile et al. | Vitamin D deficiency rickets: two cases with faulty infant feeding practices | |
| Mostafa et al. | Zinc deficiency among malnourished children under 5 years in Gaza City | |
| Lawrence | The pediatrician's role in infant feeding decision-making | |
| Maurya et al. | The Importance of Nutrition in Infancy: A Review | |
| Nucci et al. | Enteral formula use in children after small bowel transplant | |
| Shaw et al. | Nutritional considerations for the first year of life | |
| WO2001097817A1 (en) | Health promoting foods | |
| CN112772929B (en) | Calcium supplement composition and preparation method thereof | |
| Becerra-Granados et al. | Interdisciplinary management of infantile colic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |